Retatrutide and the Trump Speculation

A new experimental weight-loss drug called retatrutide is sparking major buzz after showing patients lose nearly 30% of their body weight—comparable to bariatric surgery. Developed by Eli Lilly, it targets three pathways in the body and is nearing FDA approval. The controversy erupted when a compassionate use application was filed for a 79-year-old man with severe obesity-related health issues—prompting wild speculation that it might be for Donald Trump, given his age and public interest in weight-loss meds. The White House swiftly denied any connection, though Trump has openly discussed these drugs in policy talks. The episode highlights how powerful and polarizing these new treatments have become. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/479aba5d2230366a